Despite the tremendous improvement that has been made in the past decade on funding research into diseases that are highly prevalent in developing countries, there remains a lot to be done. Currently less than 10% of the world’s biomedical research is dedicated to medical problems that account for 90% of the global burden of disease1–3. Several initiatives have began to tackle these problems but they have had varying degrees of success4, 5. These initiatives include the Roll Back Malaria project (RBM), President’s Emergency Plan for AIDS Relief (PEPFAR), Global Fund to fight AIDS, Tuberculosis and Malaria and the William J. Clinton Presidential Foundation. The focus and funding on research and services for diseases like HIV/AIDS and malaria that are highly prevalent in developing countries has therefore increased tremendously. For example, the UNAIDS reports that while there was about US$330 million available for HIV/AIDS initiative in 1996, this has grown to $4.7 billion in 2003, even though some of these programs have fallen short of their funding goals4. In addition to funding shortfall, programs have also been beset with problems associated with limited personnel and health care infrastructure in developing countries with which to meet stated goals. Historical weaknesses in the health care system of developing countries have contributed to bottlenecks in distribution and utilization of funds6. While limitations in clinical and laboratory practices have received significant attention6, the impact of limited bioethics expertise is no less significant.